biostudies-literatureFoa EBNIMH NIH HHS193-200https://www.ebi.ac.uk/biostudies/studies/S-EPMC8792795biostudies-literatureUnknown79(3)<h4>Importance</h4>Serotonin reuptake inhibitors (SRIs) are the only medications approved for obsessive-compulsive disorder (OCD), yet most patients taking SRIs exhibit significant symptoms. Adding exposure/response prevention (EX/RP) therapy improves symptoms, but it is unknown whether patients maintain wellness after discontinuing SRIs.<h4>Objective</h4>To assess whether patients with OCD who are taking SRIs and have attained wellness after EX/RP augmentation can discontinue their SRI with noninferior outcomes compared with those who continue their SRI therapy.<h4>Design, setting, and participants</h4>A 24-week, double-blind, randomized clinical trial was performed from May 3, 2013, to June 25, 2018. The trial took place at US academic medical centers. Participants included 137 adults wiJAMA psychiatryMaintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.PMC8792795R01 MH045436R01 MH045404Huppert JDWheaton MGSteinman SAKatechis MPuliafico ACapaldi STsao SDXu BDiChiara CFoa EBTyler JMiddleton RAsnaani AImms PCampeas RBGershkovich MChazin DSimpson HBRosenfield DGallagher TVermes DCahill SMoore KSanches-LaCay APinto ASnorrason ISchmidt ABKalanthroff EHahn CGHamlett GETurk-Karan EVan Meter PEfalseMaintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.<h4>Importance</h4>Serotonin reuptake inhibitors (SRIs) are the only medications approved for obsessive-compulsive disorder (OCD), yet most patients taking SRIs exhibit significant symptoms. Adding exposure/response prevention (EX/RP) therapy improves symptoms, but it is unknown whether patients maintain wellness after discontinuing SRIs.<h4>Objective</h4>To assess whether patients with OCD who are taking SRIs and have attained wellness after EX/RP augmentation can discontinue their SRI with noninferior outcomes compared with those who continue their SRI therapy.<h4>Design, setting, and participants</h4>A 24-week, double-blind, randomized clinical trial was performed from May 3, 2013, to June 25, 2018. The trial took place at US academic medical centers. Participants included 137 adults wi2022-01-01T00:00:00Z2022 Mar2026-05-08T19:57:38.873Z2025-04-05T20:23:04.021ZS-EPMC87927953508059810.1001/jamapsychiatry.2021.3997